Corporate Vice President CETA Early Portfolio

Category: Commercial Marketing

Location: Søborg, Capital Region of Denmark, DK

Do you have a strategic and commercial mindset, along with a proven track record in the pharmaceutical industry? Are you ready for a leadership role that will shape the future growth of Novo Nordisk's emerging therapies? Do you have a passion for driving and executing strategy with a high commercial impact? If so, we have an exciting opportunity for you as global Corporate Vice President, Cardiovascular & Emerging Therapy Areas (CETA) Early Portfolio and Insights.

The Corporate Vice President will report to the Senior Vice President of the commercial franchise of Cardiovascular Disease, Chronic Kidney Disease, MASH, and Early Alzheimer's Disease. Preferably, the position is based in Copenhagen, Denmark.

The Position
As the Corporate Vice President, CETA Early Portfolio & Insights, you will oversee a rapidly growing pipeline portfolio of commercial projects, significantly contributing to Novo Nordisk's long-term growth. Your key responsibilities will be managing the strategy of the broadest pipeline and portfolio in three key Therapy Areas: MASH, Cardiovascular Disease and Chronic Kidney Disease. You will lead the global New Product Planning for the strategic areas of this commercial franchise through early-stage pipeline project development. This includes responsibilities of the New Product Planning deliverables along with Commercial Guidance to Research (GtR) and Business Development (BD) teams.

You will develop commercial assessments, inputs, evaluations and competitive intelligence for all strategically important projects and late-stage assets, collaborating with launch, phase 3, portfolio and brand teams. You will chair the cross-functional Global Cardiorenal and MASH Early Commercialization Team (ECT) for our Denmark headquarters, International Operations and United States. With a forward-looking mindset, you will map current and future capabilities to stay relevant to external stakeholders and successfully execute on Novo Nordisk strategy. You will also be responsible for forecasting all Cardiovascular & Emerging Therapy Areas assets, as well as effectively manage allocated budget and related financial deliverables.

As a member of the Cardiovascular & Emerging Therapy Areas leadership team, you will lead and develop a high-performing team of 4 to 5 (senior) leaders with an overall team of approx 15 to 20 team members, focusing on a purpose-driven and honest culture, strong performance, and high level of engagement, in alignment with the Novo Nordisk Way. Additionally, you will develop, nurture and secure relationships and engagement with internal and external stakeholders to drive the Novo Nordisk agenda locally and globally. Some of the stakeholders you will closely work with include Executive Management, regional affiliates, professional and patient organisations and Academia.

Qualifications
To succeed in this role, we expect you to have:

• A master's degree preferably in business or a science-related field.
• 10+ years of pharmaceutical industry experience, with a strong understanding of the value chain (early product development, lifecycle management, launches, commercial strategy (both short and long-term), affiliate execution incl. P&L understanding).
• Experience working operationally with affiliates or with business development, portfolio, pipeline and phase 3 assets.
• Experience working with R&D, marketing, pharmaceutical products, or medical devices in a large organization.
• Experience entering new therapy areas and managing alliances and partnerships.
• Strong leadership experience – delivering proven results through a high performing team.
• The ability to navigate complexity by managing multiple projects, delivering high-quality results on time, and a strong results-oriented approach.
• Excellent stakeholder management skills, good communication and presentation skills.
• A strategic and analytical mindset.
• Readiness to embrace change and bring a high energy level, curiosity and ambition.
• Fluency in written and spoken English.

About the Department
The CETA franchise is located in Søborg, Denmark, and focuses on Cardiovascular Disease, MASH, Chronic Kidney and Early Alzheimer's Disease (AD) therapeutic areas. The franchise is a growing area within Novo Nordisk.

Joining our team means becoming part of a dynamic and innovative department. We value curiosity, ambition, and a commitment to making a difference in the lives of patients around the world.

Contact
For further information, Senior Executive Search Partner, Anette Schmidt Jepsen can be contacted at atjp@novonordisk.com from Monday 6 January until application deadline on Wednesday 15 January 2025. If you believe that you are qualified and willing to take the challenge, please send your CV and relevant documentation directly via our online application tool.

Deadline
Please submit your application via our online application tool by Wednesday 15 January 2025.
You do not need to attach a cover letter to your application, but please include a few sentences about why you are applying in your resume or CV. To ensure an efficient and fair recruitment process, please refrain from adding a photo in your CV.

We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.

At Novo Nordisk we recognize that it is no longer good enough to aspire to be the best company in the world. We need to aspire to be the best company for the world and we know that this is only possible with talented employees with diverse perspectives, backgrounds and cultures. We are therefore committed to creating an inclusive culture that celebrates the diversity of our employees, the patients we serve and communities we operate in. Together, we're life changing.